GlassScriptPhysician profile
Jerald P Marifke
NPI 1821091679
$960.50
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $267 · 2021: $439.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $355.75 | 2021 | |
| Tandem Diabetes Care, INC. | $160.92 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Amgen INC. | $89.31 | 2020 | |
| Medtronic Minimed, INC. | $84.68 | 2019-2020 | |
| Corcept Therapeutics | $83.26 | 2021 | |
| Ibsa Pharma INC. | $61.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Marifke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.